What is Atosiban Market?
Over recent decades, the frequency of preterm birth in most Western countries seems to be increasing rather than decreasing, according to the research 24% or one four children born prematurely across the globe. Increasing incidences of preterm birth, various pregnancies, infections, and chronic conditions, for example, diabetes and hypertension among pregnant ladies are driving the development of the atosiban market. Atosiban is a potent stimulator of myometrial contractions and assumes a significant part in the inception of both term and preterm labor. It is used after assisted reproduction, preterm birth, and to halt premature labor due to its ability to decrease contractions and improve uterine receptivity by reducing intracytoplasmic calcium release and downregulate prostaglandin synthesis. As per the World Health Organization, consistently, an estimated 15 million infants are born preterm and this figure is rising step by step. Across 184 nations, the pace of preterm birth goes from 5% to 18% of babies born.
The market study is being classified by Type (Injection and Concentrate), by Application (Suppression of Preterm Labour and Others) and major geographies with country level break-up.
Ferring Pharmaceuticals (Switzerland), Sun Pharmaceutical Industries (India), Shanghai Soho-Yiming Pharmaceuticals Co.,Ltd.(China), EVER NEURO PHARMA GMBH (Austria), Cayman Chemical (United States), Hemmo Pharmaceuticals Pvt Ltd (India), GlaxoSmithKline plc. (United Kingdom) and Xiamen Neore Pharmaceutical Technology Co., Ltd (China) are some of the key players profiled in the study.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that China Players will contribute to the maximum growth of Global Atosiban market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Atosiban market by Type, Application and Region.
On the basis of geography, the market of Atosiban has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rise in the incidence of multiple pregnancies, infections, and chronic conditions
- High incidence of the complications in birth occuring
- Global efforts to further reduce child mortality demand urgent action to address preterm birth
- Adverse effect of the atosiban such as Nausea
- Drugs registered for Atosiban are restricted
- Increasing incidences of preterm birth
- Emerging demand from the countries such as India, China owing to highest preterm birth burden
- Lack of hospital facilities
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Atosiban Manufacturer, Government Regulatory and Research Organizations and End Use Industry
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase